Showing results (591-600 of 772) with videos related to
Sort By:
Pageof 78
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 11, 2013
High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasisRobert A A van Boerdonk, Johannes M A Daniels, Elisabeth Bloemena, et al.Hormones & Cancer|August 16, 2014
Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancersAnieta M Sieuwerts, Scooter Willis, Michael B Burns, et al.Journal of Clinical Pathology|June 12, 2014
Combined sputum hypermethylation and eNose analysis for lung cancer diagnosisA Jasmijn Hubers, Paul Brinkman, Remco J Boksem, et al.Chest|May 27, 2023
Update on Biomarkers for the Stratification of Indeterminate Pulmonary NodulesRafael Paez, Michael N Kammer, Nicole T Tanner, et al.International Journal of Cancer|November 9, 2023
High-risk human papillomavirus distribution according to human immunodeficiency virus status among women with cervical cancer in Abidjan, Côte d'Ivoire, 2018 to 2020Simon P Boni, Vanessa Tenet, Apollinaire Horo, et al.CHEST Pulmonary|May 13, 2024
The Lung Cancer Prediction Model "Stress Test": Assessment of Models' Performance in a High-Risk Prospective Pulmonary Nodule CohortBrent E Heideman, Michael N Kammer, Rafael Paez, et al.Journal of Clinical Microbiology|August 8, 2008
Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasiaA T Hesselink, M A P C van Ham, D A M Heideman, et al.Oncotarget|May 28, 2015
NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitorElena Galvani, Jing Sun, Leticia G Leon, et al.Scientific Reports|April 15, 2023
Longitudinal lung cancer prediction convolutional neural network model improves the classification of indeterminate pulmonary nodulesRafael Paez, Michael N Kammer, Aneri Balar, et al.Plos One|August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.Pageof 78